🟢 Anixa Biosciences is trading 5.37% up in pre-market as broader biotechnology strength lifts the sector

Anixa Biosciences is trading 5.37% up at $3.86 as broader biotechnology strength lifts the sector.

• XBI gained 2.06% during the August 25 regular session, providing the clearest explanation for the pre-market move.
• The latest announcement concerns a September 9–11 healthcare conference presentation covering existing breast-cancer vaccine and ovarian CAR-T programs.
• It was not related to earnings, regulatory approval, financing, or newly released trial results.